Background: Women with Polycystic Ovary Syndrome (PCOS) have a large number of small follicles in the pre-antral and antral stages and their AMH serum concentrations is higher than normal women. So Anti-Mullerian hormone (AMH) may have a role in disordered folliculogenesis in women with PCOS. Today, blood glucose lowering and type 2 diabetes drugs, espe- cially metformin, are widely used in the treatment of PCOS(3). Since it has been suggested that insulin ply an important role in the pathophysiology of PCOS, Some studies have focused to investigate the serum level of AMH during treatment with metformin in patients with PCOS. Sitagliptin, as an oral anti- hyperglycemic agent, is used in the treatment of diabetes mel- litus type 2, and recently is considered as an antihyperglycemic agent in the treatment of type 2 diabetes and clinical investiga- tions of PCOS. The aim of this study was to compare the effects of metformin and sitaformin (a combination product abstained from sitagliptin and metformin) on serum levels of AMH in the PCOS patients suffering from infertility. Materials and Methods: In this clinical trial, 60 infertile PCOS patients were selected based on the Rotterdam criteria and candidate for IVF/ICSI. Then they divided into 3 groups (n=20) including metformin (500 mg of metformin/ two times per day) group, sitaformin (50/500 mg of sitaformin/ two times per day) group and placebo group. All patients were undergoing treatment with antagonist GnRH protocol. In all groups, medi- cations were administrated from the day 3 of the previous cycle to the egg pancreas. Data was analyzed statistically using one- way ANOVA and Tukey’s test and the means difference was consider significantly different at P<0.05. Results: A significant decrease in the Serum level of AMH was found in the metformin and sitaformin groups when compared to the placebo-treated group(p≤0.03). Meanwhile this param- eter significantly decreased in the sitaformin group compared to the metformi
